Podiatry Equipment Market Key Drivers & On-going Trends 2017 – 2025

Podiatry is a medical specialty that deals in the diagnosis, prevention, and treatment of a wide range of ankle and foot diseases, defects, and injuries. Podiatrists diagnose and treat foot problems caused due to underlying medical conditions such as diabetes and arthritis. Different types of equipment, devices, and systems are used for the accurate diagnosis and treatment of various types of foot disorders, diseases, and injuries, including ingrown toenails, heel and arch pains, and skin problems. This equipment includes podoscopes, podiatry chairs, podiatric drills and lasers, biopsy kits and instruments, podiatry lights, scissors and nippers, and other products. Podoscopes are widely used for the diagnosis of foot and ankle disease and injuries.

View Report-

https://www.transparencymarketresearch.com/podiatry-equipment-market.html

Global Podiatry Equipment Market: Drivers and Restraints

The global podiatry equipment market is projected to be driven by high prevalence and rising incidence of podiatry diseases and arthritis and diabetes worldwide. A large proportion of the adult population is affected by foot pain, Achilles tendonitis, bunions, ankle pain, hammer toe, and claw toe worldwide. It is estimated that about 19% of the population of the U.S. has an average of 1.4 foot problems each year. Diabetes is one of the leading causes of foot complications worldwide that causes several foot disorders such as tingling and pain, low blood supply in feet, and foot ulcers. Technological advancements in diagnostic and treatment podiatric devices, new product developments, and favorable medical reimbursement policies are projected to fuel the podiatry equipment market during the forecast period. Moreover, increased awareness about foot diseases, and rise in demand for preventive health care in developed countries is likely contribute to the expansion of the podiatry equipment market. On the other hand, the high cost of equipment is projected to restrain the podiatry equipment market during the forecast period.

Brochure Download-

https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=40922

Global Podiatry Equipment Market: Key Segments

The global podiatry equipment market can be segmented based on product, end-user, and region. In terms of product, the global podiatry equipment market can be classified into operating units, podiatry chairs, diagnostic devices, accessories, and others. The operating units segment is projected to account for a prominent podiatry equipment market share by the end of 2025. The operating units segment can be further sub-divided into podiatry workstations, podiatry drills, podiatry shock wave therapy devices, podiatry lasers, surgical lights, and others. The diagnostic devices segment can be further split into podoscopes, baropodometry platforms, orthopedic 3D scanners, and others. The podoscope sub-segment is projected to be highly lucrative and is likely to expand at  rapid CAGR during the forecast period. A podoscope is a diagnostic device that uses highly polarized light for the detection of orthopedic foot defects. Podoscopes help to determine the root cause of painful walking, deformities, leg pain, ligament damage, and other ailments of the legs. The accessories segment can be further categorized into nail scissors & nippers, black files and probes, biopsy packs, and others. Based on end-user, the global podiatry market can be segmented into hospitals, ambulatory surgery centers, and specialty clinics. The hospitals segment is projected to dominate the global podiatry equipment market by the end of 2025.

Request For Discount-

https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=40922

In terms of region, the global podiatry equipment market can be classified into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is projected to dominate the global podiatry equipment market by the end of 2025. A large number of adults and children in the U.S. are diagnosed with the foot problems. It is estimated that around 75% of people in the U.S. will experience foot problems in their lifetime. Well-established health care facilities, easy access to healthcare facilities, and high levels of awareness about foot and ankle disorder in the region are estimated to drive the podiatry equipment market in the region. Europe is also likely to constitute a significant share of the global podiatry equipment market. The market in the Asia Pacific is estimated to expand at a significant CAGR during the forecast period. The podiatry equipment market in Latin America and Middle East & Africa is projected to expand at moderate pace during the forecast period.

Global Podiatry Equipment Market: Key Players

Key players operating in the global podiatry equipment market include Erchonia Corporation, Sheaumann Laser, Inc., Elektronische Steuergeräte GmbH, NAMROL GROUP, Vismara s.r.l., Sensor Medica, S.M.D. Srl, Mariotti & C. srl, ELLA LEGROS, and CHINESPORT S.p.a..

The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.

About us:
Transparency Market Research (TMR) is a U.S.-based provider of syndicated research, customized research, and consulting services. TMR’s global and regional market intelligence coverage includes industries such as pharmaceutical, chemicals and materials, technology and media, food and beverages, and consumer goods, among others. Each TMR research report provides clients with a 360-degree view of the market with statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.

Contact us:
Transparency Market Research
90 State Street,
Suite 700,
Albany
NY – 12207
United States
Tel: +1-518-618-1030
USA – Canada Toll Free 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/

Advertisements

Cystinosis Disease Therapeutics Market Report Explored in Latest Research 2017-2025

Cystinosis is a rare disease and characterized by accumulation of cystine (a building block of proteins) inside cells. Increase in cystine damages cells and frequently forms crystals that can develop and cause issues in numerous organs and tissues. The kidneys and eyes are particularly defenseless to the damage. Muscles, thyroid, pancreas, and testicles could also be affected. Nephropathic cystinosis, intermediate cystinosis, and non-nephropathic cystinosis are the three types of cystinosis. Cystinosis disease can effect both adults and children. However, the prevalence is high in children. Juvenile nephropathic cystinosis is the most common and serious type of cystinosis disease. In cystinosis disease, a large amount of salts and glucose, bicarbonate, phosphate, potassium, and certain amino acid being excreted through the urine. This is one of the major complications of cystinosis infection (failure of kidneys) in children. In adults, cystine generally accumulates in the cornea of the eyes. Symptoms of cystinosis disease includes dehydration, vomiting, metabolic acidosis, constipation, and polyuria.

View Report-

https://www.transparencymarketresearch.com/cystinosis-disease-therapeutics-market.html

Based on treatment type, the global cystinosis disease therapeutics market can be segmented into symptomatic therapy, renal replacement therapy, and hormonal therapy. The symptomatic therapy segment is likely to expand at a rapid pace during the forecast period. The symptomatic therapy is the maintenance of fluid, electrolyte balance in the body. So, most of the doctors prefer to give dose of potassium, sodium, and phosphate substantially in addition with cystine deleting agents like Cysteamine which effectively lowers the cystine content in the cells of a patients with in short time and retain the body fluid. Moreover, the symptomatic therapy is cost effective than the other type of therapy, for this reason the symptomatic therapy segment is expected to grow at a significant pace during the forecast period.  In terms of test type, the market can be classified into blood test, molecular test, urine test, slit lamp examination, and others. The blood test segment is likely to expand at a rapid pace during the forecast period.

Brochure Download-

https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=40976

Growing concerns about the effect of cystinosis disease in kidney, liver, and eye is one of the major factors propelling the market. Moreover, rise in awareness about mutation screening to avoid gene mutation drives the cystinosis disease therapeutics market. However, limited treatment options and lack of focus on research & development are likely to hamper the cystinosis disease therapeutics market in the next few years.

Request For Discount-

https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=40976

In terms of region, the global cystinosis disease therapeutic market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Cystinosis, especially nephropathic cystinosis, is likely to affect many people in the U.S. Moreover, adoption of different types of therapy to cure cystinosis is expected to augment the cystinosis disease therapeutics market in North America. Europe is also a lucrative market for cystinosis disease therapeutics. Increase in demand for treatment and rise in patient awareness about different treatment options are anticipated to fuel the growth of the cystinosis disease therapeutics market in Europe. The cystinosis disease therapeutics market is Asia Pacific is projected to be driven by increase in population, better treatment options, and rise in demand for rapid diagnosis. Latin America and Middle East & Africa are expected to be moderate contributors to the global cystinosis disease therapeutics market.

Key players operating in the global cystinosis disease therapeutics market are Horizon Pharma plc, Mylan N.V., Novartis AG, and Gilead Sciences, among others.

The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.

About us:
Transparency Market Research (TMR) is a U.S.-based provider of syndicated research, customized research, and consulting services. TMR’s global and regional market intelligence coverage includes industries such as pharmaceutical, chemicals and materials, technology and media, food and beverages, and consumer goods, among others. Each TMR research report provides clients with a 360-degree view of the market with statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.

Contact us:
Transparency Market Research
90 State Street,
Suite 700,
Albany
NY – 12207
United States
Tel: +1-518-618-1030
USA – Canada Toll Free 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/

Nitric Oxide Drugs & Therapeutics Market Size, Growth, Trends and 2025 Forecast Report

Nitric oxide generates free radicals of oxygen and acts as a scavenger in the body. It functions as a signaling molecule and performs pathogenesis for several diseases. Major advancements in clinical areas has transformed biotechnology and medicine. The discovery of nitric oxide drugs and therapeutics is important since it is an effective cardiovascular medicine. Signal transmission is an entirely new principle for biological systems. A continuous and regulated method is required for generating nitric oxide which is essential for cardiovascular systems, immune and nervous systems. The medical devices technique expands the capabilities of nitric oxide drugs & therapeutics, and enables new diagnostic & treatment applications for patients. Many research institutes and laboratories are focusing on delivery of nitric oxide by different technologies. Modulation of unique technology and approach ensures better functional ability. New developments in pharmacological and gene therapy approaches allow to identify the diseases or infection at the cellular and molecular level, which is paving the way for early diagnosis and treatment of diseases.

View Report-

https://www.transparencymarketresearch.com/nitric-oxide-drugs-therapeutics-market.html

High prevalence of neural disorders and cardiovascular diseases, rising patient awareness, increasing research and development initiatives, advent of high-throughput screening (HTS) for drug discovery, and genomic technology are key factors driving the nitric oxide drugs & therapeutics market. In 2017, the WHO estimated that 17.7 million people died from cardiovascular diseases (CVDs) in 2015. Of these deaths, 6.7 million were due to stroke and 7.4 million were due to coronary heart disease. The cardiovascular disease burden can be reduced through early detection of heart attack and providing awareness education about the risk of disease among patients who develop cholesterol at a very early age. Increasing number of patients with neural diseases, rising geriatric population, and increasing awareness about therapeutics & drugs, are projected to fuel the overall nitric oxide drugs & therapeutics market. However, factors such as cost of drugs, and lengthy procedures, are expected to hamper the nitric oxide drugs & therapeutics market.

Brochure Download-

https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=40952

The global nitric oxide drugs & therapeutics market can be segmented based on drug type, delivery type, therapy, application, end-user, and region. In terms of drug type, the Nitric Oxide Drugs & Therapeutics Market can be classified into inorganic drugs, donating drugs, hybrid drugs and others. In terms of delivery, the market can be classified into topical delivery, nano particle delivery, and others. In terms of therapy, the Nitric Oxide Drugs & Therapeutics Market can be divided into inhalation therapy, gene therapy, vascular therapy, and others. In terms of application, the Nitric Oxide Drugs & Therapeutics Market is segmented into inflammatory disorders, cardiovascular diseases, inflammation, erectile dysfunction, and neuroprotection. Nano particle delivery is a rapidly expanding segment owing to the increase in funds in research and technology, globally. In terms of end-user, the Nitric Oxide Drugs & Therapeutics Market can be segregated into diagnostic laboratories, pathology labs, life sciences and research lab, and others. In terms of region, the Nitric Oxide Drugs & Therapeutics Market can be segmented into North America, Latin America, Europe, Asia Pacific, and Middle East & Africa.

Request For Discount-

https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=40952

Geographically, North America dominates the global nitric oxide drugs & therapeutics market due to the increase in funding for the development of research and health care infrastructure. Rising incidence of cardiovascular diseases and early phase diagnosis and treatment of diseases are driving the biotechnology segment, which in turn is expected to boost the nitric oxide drugs & therapeutics market in North America. Europe is the second largest Nitric Oxide Drugs & Therapeutics Market, as there are favorable government policies regarding the development of health care infrastructure and gene therapy companies. The Nitric Oxide Drugs & Therapeutics Market in Asia Pacific is expected to expand at a high growth rate during the forecast period due to rising population, changing lifestyle, increasing awareness among patients, and rising per capita expenditure. Additionally, the economic growth in India and China is supporting the health care infrastructure as well as expansion of pharmaceutical companies and biotech labs.

Major players operating in the global nitric oxide drugs & therapeutics market include Third Pole, Inc., Novan, Inc., Mallinckrodt, Pulmonox Group, AOBiome, LLC., Novoteris, LLC., Neogenis, Inc. and others.

The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.

About us:
Transparency Market Research (TMR) is a U.S.-based provider of syndicated research, customized research, and consulting services. TMR’s global and regional market intelligence coverage includes industries such as pharmaceutical, chemicals and materials, technology and media, food and beverages, and consumer goods, among others. Each TMR research report provides clients with a 360-degree view of the market with statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.

Contact us:
Transparency Market Research
90 State Street,
Suite 700,
Albany
NY – 12207
United States
Tel: +1-518-618-1030
USA – Canada Toll Free 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/

Community Acquired Pneumonia (CAP) Market Latest Trends, Demand and Analysis 2024

Community-acquired pneumonia (CAP) has been a leading cause of mortality among people with infectious diseases and affects people of all age groups. CAP is mainly bacterial in nature and can be caused by a wide range of microorganisms; the most common being streptococcus pneumoniae (pneumococcus). Other pathogens include Haemophilus influenzae, mycoplasma pneumoniae, Chlamydia pneumoniae, and Legionella sp.

View Report-

https://www.transparencymarketresearch.com/community-acquired-pneumonia-market.html

Increasing prevalence of specific risk factors for CAP in patients has contributed to rising incidence of the infection across various regions. The infection accounts for a significant number of hospital admissions every year. Fuelled by substantial economic and clinical burden of the infection worldwide, a host of treatment modalities to manage CAP has recently emerged. They focus on managing antimicrobial resistance for the most common pathogens, particularly among geriatric population, and evaluating the various vaccination options to prevent these infections. In addition, advancement in diagnostic technologies has increased awareness related to disease incidence, especially in developed nations, thereby fuelling the growth of the market.

The report offers in-depth insight into the key drivers and restraints, current diagnostic trends, emerging treatment modalities, regulatory landscape, market share and size of major segments, and competitive landscape. The strategically motivated insights help various stakeholders gain a better understanding of the market dynamics and identify imminent investment pockets.

Brochure Download-

https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=4314

Global Community Acquired Pneumonia (CAP) Market: Trends and Opportunities

Rising prevalence of CAP across various regions and the increasing awareness regarding the related diagnostics and therapeutics are the key factors propelling the market. An expanding ageing population, especially in developed countries, is associated with comorbid disease conditions, which has stimulated the demand for advanced CAP treatments. In addition, the concomitant incidence of human immunodeficiency virus (HIV) infection among adult population has increased the morbidity of CAP in some regions, catalyzing the market growth.

Request For Discount-

https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=4314

However, the rising case of antibiotic-resistant pathogens has hindered the efficacy of antimicrobial treatments and vaccines. This is likely to impede the growth of the market to an extent. Nevertheless, numerous clinical studies in understanding the etiology of the infection and the launch of new biomarkers that help in better risk stratification of patients affected by CAP are crucial developments creating promising opportunities for market players. In addition, the release of the newer pneumococcal conjugate vaccines is anticipated to expand the treatment modalities of CAP.

Global Community Acquired Pneumonia (CAP) Market: Regional Outlook

Europe and North America are prominent markets for community acquired pneumonia. The growth of the regional markets is expected to be driven by robust healthcare infrastructure and increasing awareness about the availability of advanced biomarkers and diagnostic tests. The advent of new treatment therapies, including vaccines, is anticipated to boost the regional market.

Meanwhile, Asia Pacific is expected to expand at an impressive CAGR over the forecast period. Expanding healthcare infrastructure, driven by booming medical tourism in developed and developing countries, and substantial government funding to augment healthcare facilities are the key factors spurring the demand for CAP treatments in Asia Pacific. Furthermore, increasing discretionary spending on healthcare in various countries is expected to propel the Asia Pacific market in the coming years.

About us:
Transparency Market Research (TMR) is a U.S.-based provider of syndicated research, customized research, and consulting services. TMR’s global and regional market intelligence coverage includes industries such as pharmaceutical, chemicals and materials, technology and media, food and beverages, and consumer goods, among others. Each TMR research report provides clients with a 360-degree view of the market with statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.

Contact us:
Transparency Market Research
90 State Street,
Suite 700,
Albany
NY – 12207
United States
Tel: +1-518-618-1030
USA – Canada Toll Free 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/

Antidiabetics Market Dynamics, Forecast, Analysis and Supply Demand 2023

The anti-diabetics market includes drugs, which are used for treatment of diabetes mellitus and are also known as oral hypoglycemic/antihyperglycemic agents. The anti-diabetics market has grown tremendously in recent years with increasing prevalence of diabetes mellitus. Thus, systemic therapies for diabetes have become the focal point of attention due to the burgeoning diabetic population size, with diabetes affecting middle age groups and children across all income groups globally.

View Report-

https://www.transparencymarketresearch.com/antidiabetics-market.html

The anti-diabetics market has been segmented based on type of drug class into biguanides (metformin), sulfonylureas (glimepiride), meglitinides (repaglinide), thiazolidinediones (pioglitazone), dipeptidyl peptidase IV (DPP-IV) inhibitors (sitagliptin), and α-glucosidase inhibitors (acarbose).

Among these drug classes, Biguanides act directly against insulin resistance. Sulfonylureas (SUs) were the earliest drug classes in the market for treatment of diabetes and have a significant market presence. α-glucosidase inhibitors delay postprandial glucose absorption by hydrolysis of disaccharide is into monosaccharide’s in the small intestine.  Meglitinides are prandial insulin releasers that stimulate rapid insulin secretion. The thiazolidinediones are insulin-sensitizing drugs, which improve whole-body insulin sensitivity through gene regulation. DPP-IV inhibitors make a significant impact on glucose tolerance and make lasting improvements in the health outcomes of diabetic patients.

Some of the major drivers and opportunities for growth of this market include drug combinations of several agents such as sitagliptin and metformin and other drug combinations that are in different stages of clinical and pipeline development. Increase in the prevalence of diabetes and new product launches by major pharmaceutical companies re some of the key drivers for growth in this market. In 2015, Boehringer Ingelheim GmbH launched two new drugs (Synjardy & Glyxambi)for treatment of diabetes mellitus type II.

Brochure Download-

https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=8809

Some of the key opportunities for the antidiabetics include a strong pipeline for antidiabetics and entry of new players in the market, for instance, Novo Nordisk’s diabetes drug’s Tresiba, and Ryzodeg received FDA approval in September 2015. Moreover, Boehringer Ingelheim GmbH has a strong pipeline for anti-diabetic drugs, such as Linagliptin which is a dipeptidyl peptidase (DPP) 4 inhibitor) for patients suffering from diabetes mellitus type II and high cardiovascular risk.

However, despite the availability of numerous branded antidiabetic drugs, many of these drugs have lost patent protection. In the wake of huge pressures from government and regulatory authorities, which have banned top selling drugs in various countries, in order to promote generic drugs at lower costs for diabetic patients. For instance, Mankind Pharma, launched anti-diabeticDynaglipt (Teneligliptin) under the drug class DPP-4 inhibitors in November 2015 in India targeting the middle to low income diabetic patient population.

Request For Discount-

https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=8809

As a result, the volume of antidiabetics is expected to shift to first generation drugs and other generic drugs in the market. Moreover, there is a huge unmet medical need for antidiabetics that can treat multiple chronic disorderscoexisting with diabetessuch as cardiovascular diseases, dyslipidemia, hypertension etc. Another major restraint in the antidiabetics market is reduction in the efficacy of drugs over a period and canlead to other health complications.

Some of the major players in the market include Astra Zeneca plc, Boehringer Ingelheim GmbH, Eli Lilly & Co., Johnson & Johnson, Mankind Pharma Ltd., Merck & Co. Inc., Novartis AG, Novo Nordisk A/S, SanofiS.A., and Teva Pharmaceutical Industries Ltd.

About us:
Transparency Market Research (TMR) is a U.S.-based provider of syndicated research, customized research, and consulting services. TMR’s global and regional market intelligence coverage includes industries such as pharmaceutical, chemicals and materials, technology and media, food and beverages, and consumer goods, among others. Each TMR research report provides clients with a 360-degree view of the market with statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.

Contact us:
Transparency Market Research
90 State Street,
Suite 700,
Albany
NY – 12207
United States
Tel: +1-518-618-1030
USA – Canada Toll Free 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/

Postmenopausal Vaginal Atrophy PVA Drugs Market Analysis by Recent Trends, and Growth Forecast 2023

Postmenopausal vaginal atrophy (PVA) refers to an inflammatory disease affecting the vagina and is characterized by the inflammation, reduced elasticity of vaginal tissues, thinning, and drying, of the vaginal walls. The chief cause of the condition is a serious drop in the estrogen levels on females, often due to hormonal changes that the body undergoes on the onset of and post menopause. Common symptoms of the condition include irritation, redness, burning sensation, and dyspareunia. A number of branded and generic drugs are available in the market for the treatment of postmenopausal vaginal atrophy.

View Report-

https://www.transparencymarketresearch.com/postmenopausal-vaginal-atrophy-pva-drugs-market.html

The report contains a detailed portrayal of the key factors that influence the overall development of the global PVA drugs market. The report uncovers the key factors that impact the market with the intention of providing the readers an all-encompassing view of the aspects that need to be considered when venturing into the market or developing new growth strategies. The report also analyzes all the factors that have notably influenced the market in the past few years and the ones that could prove to be influential for the market in the next few years. Through a number of competent forecast methodologies, the report attempts at deducing where the global PVA drugs market is headed.

Global Postmenopausal Vaginal Atrophy (PVA) Drugs Market: Trends and Opportunities

The global postmenopausal vaginal atrophy drug market is headed along a healthy growth path due to a number of factors, with the most prominent ones being the increasing percentage of aging population, introduction of favorable healthcare reforms in several regions, and a vast set of unmet medical needs in emerging and less-developed economies. The introduction of top non-estrogen-based drugs has also helped the market gain pace in the recent years. In addition, the enhancement of the healthcare reforms for meeting the requirements to treat vaginal atrophy is also a chief factor fuelling the development of the market. However, the introduction of a number of economically priced generic medicines may inhibit the growth of this market in the coming years.

Brochure Download-

https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=8203

However, the market continues to be challenged by factors such the low rate of diagnosis of the condition, lack of patient compliance to treatments, and reluctance of women to discuss about aspects such as discomfort during intercourse, vaginal dryness, and vaginal burning with healthcare professionals, which results in the low rate of diagnosis and treatment. Nevertheless, the advent of new drug varieties with improved promise of safety and changing perspectives regarding sexuality and it’s medical complications could help the market gain pace in the next few years. Factors such as the rise in number of encouraging healthcare reforms such as the Affordable Care Act could also help accommodate the medical condition in a better manner globally.

Global Postmenopausal Vaginal Atrophy (PVA) Drugs Market: Geographical and Competitive Dynamics

Geographically, the global PVA drugs market is presently dominated by North America as the region is powered by a well-developed healthcare industry, has a high level of awareness about the available treatment options for PVA among women, and the willingness to discuss about the occurrence and symptoms of PVA freely. The market in Europe is also highly promising owing to the early rate of diagnosis and well-established healthcare and pharmaceutical industries.

Some of the leading companies operating in the global PVA drugs market are Endoceutics, Inc., Actavis plc, Pfizer, Inc., Bionovo, Inc., Therapeutics MD, Inc., Novo Nordisk A/S, Teva Pharmaceuticals Ltd., and Shionogi & Co. Ltd.

Request For Discount-

https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=8203

The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.

About us:
Transparency Market Research (TMR) is a U.S.-based provider of syndicated research, customized research, and consulting services. TMR’s global and regional market intelligence coverage includes industries such as pharmaceutical, chemicals and materials, technology and media, food and beverages, and consumer goods, among others. Each TMR research report provides clients with a 360-degree view of the market with statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.

Contact us:
Transparency Market Research
90 State Street,
Suite 700,
Albany
NY – 12207
United States
Tel: +1-518-618-1030
USA – Canada Toll Free 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/

Antiepileptic Drugs Market Dynamics, Forecast, Analysis and Supply Demand 2023

Antiepileptic drugs are therapies approved to treat patients with epilepsy, a brain disorder in which clusters of nerve cells signal abnormally, which can lead to seizures. These seizures are incidents that occur when group of nerve cells or neurons in brain sends wrong signals. Patients suffering from epilepsy may complain about strange emotions and sensations or they may behave strangely. Epilepsy is the fourth most common brain disorder affecting people of all ages. The causes of epilepsy are undetermined however major risk factors involved include brain injury, brain tumor, stroke, and substance use disorders. For the treatment of epilepsy, antiepileptic medicines (AEDs) are prescribed, preference of the drug depending on the age of the patient, type of seizures to be treated, seriousness of the seizures, and part of the brain involved. Alcoholism, smoking, changing lifestyle and rising geriatric population are the major factor driving the antiepileptic market.

View Report-

https://www.transparencymarketresearch.com/antiepileptic-drugs-market.html

The market for antiepileptic drugs is broadly classified on the basis of first generation antiepileptic drugs and second generation antiepileptic drugs and pipeline drugs. First generation antiepileptic drugs consists of Valproate (Depakote), Oxycarbazepine ((Trileptal), Carbamazepine (Carbatrol), Phenobarbital (Luminal), Primidone (Mysoline), Ethosuximide (Zarontin), Topiramate (Topamax) Phenytoin (Dilantin, Phenytek). Second generation antiepileptic drugs consist of different mechanism of action than the first generation drugs. These consists of Lamotrigine (Lamictal), Pregabalin (Lyrica), Eslicarbazepine acetate Zonisamide (Zonegran), Lacosamide (Vimpat), Levetiracetam (Keppra), (Aptiom/Zebinix),  Perampanel (Fycompa), Rufinamide (Banzel/Inovelon), Ezogabine/retigabine (Trobalt/Potiga),. First generation antiepileptic drugs majorly carbamazepine, valproate, phenytoin and oxycarbazepine are dominating the epilepsy therapeutics market. However, second generation AEDs such as levetiracetam, zonisamide and lacosamide are slowly overtaking the antiepileptic drugs market due to its improved tolerability and efficacy.

The pipeline for antiepileptic drugs has been segmented on different phases. The drugs in the phase III of the pipeline include Brivaracetam (UCB Pharma Ltd), Ganaxolone (Marinus Pharmaceuticals), USL261 (Upsher Smith Laboratories, Inc.), Perampanel (Eisai Co) and YKP3089 (SK Life Sciences) and others. The phase I and II of the pipeline drugs include Buspirone, Everoline, UCB0942 (PPSI), Lacosamide, GWP42006, TAK-932 and others. All this drugs are currently under clinical trials and it is expected that these drugs will prove beneficial for epilepsy therapeutics market.

Brochure Download-

https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=7664

Geographically, North America dominates the global antiepileptic drugs market followed by Europe majorly due to the extensive research and development activities in the neurology and the presence of pharmaceutical industries in the region. Epilepsy affects approximately 2.5 million people in the United States, and results in an estimated annual cost of approximately $15.5 billion in healthcare. Three new antiepileptic drugs have been approved in U.S. since 2012 including ezogabine/retigabine, perampanel and eslicarbazepine acetate. Continuous increase in uptake of second generation antiepileptic drugs is also driving the antiepileptic drugs market in North America and Europe. Asia-Pacific is also increasing constantly in the antiepileptic drugs market mainly due to the high prevalence of epilepsy in India and China, increased penetration due to better market access options in China and expected approval of drugs with novel mechanisms are some of the factors responsible for expanding the epilepsy therapeutics market in the Asia-Pacific region. Latin America is also a growing market for antiepileptic drugs due to developing healthcare expenditure and high prevalence rate of epilepsy in the region.

Some of the major players in epilepsy therapeutics market include Abbott Laboratories, Cephalon, Inc, GlaxoSmithKline plc,., Johnson & Johnson, Novartis AG, Pfizer, Inc., Sunovion Pharmaceuticals, Inc., Valeant Pharmaceuticals International, Inc., Sanofi S.A. and UCB Pharma Ltd.

Request For Discount-

https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=7664

This research report analyzes this market on the basis of its market segments, major geographies, and current market trends. This report provides comprehensive analysis of

  • Market growth drivers
  • Factors limiting market growth
  • Current market trends
  • Market structure
  • Market projections for upcoming years

This report is a complete study of current trends in the market, industry growth drivers, and restraints. It provides market projections for the coming years. It includes analysis of recent developments in technology, Porter’s five force model analysis and detailed profiles of top industry players. The report also includes a review of micro and macro factors essential for the existing market players and new entrants along with detailed value chain analysis.

About us:
Transparency Market Research (TMR) is a U.S.-based provider of syndicated research, customized research, and consulting services. TMR’s global and regional market intelligence coverage includes industries such as pharmaceutical, chemicals and materials, technology and media, food and beverages, and consumer goods, among others. Each TMR research report provides clients with a 360-degree view of the market with statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.Contact us:
Transparency Market Research
90 State Street,
Suite 700,
Albany
NY – 12207
United States
Tel: +1-518-618-1030
USA – Canada Toll Free 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/